(Q37848043)

24 August 2017

1 reference

title

Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans (English)

1 reference

24 August 2017

0 references

0 references

James F List

1

1 reference

PubMed ID

21358698

24 August 2017

Jean M Whaley

series ordinal

2

1 reference

24 August 2017

1 March 2011

1 reference

Kidney International. Supplement

24 August 2017

1 reference

24 August 2017

120

1 reference

24 August 2017

S20-7

1 reference

https://scigraph.springernature.com/pub.10.1038/ki.2010.512

24 August 2017

0 references

cites work

Active sugar transport in health and disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.512

7 January 2021

Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.512

7 January 2021

Inhibitor binding in the human renal low- and high-affinity Na+/glucose cotransporters

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.512

7 January 2021

Renal Na(+)-glucose cotransporters

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.512

7 January 2021

Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.512

7 January 2021

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.512

7 January 2021

Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.512

7 January 2021

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.512

7 January 2021

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.512

7 January 2021

Insulin resistance in rats with non-insulin-dependent diabetes induced by neonatal (5 days) streptozotocin: evidence for reversal following phlorizin treatment.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.512

7 January 2021

Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.512

7 January 2021

Effects of phlorizin and acipimox on insulin resistance in STZ-diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.512

7 January 2021

Diagnosis of insulin resistance and associated syndromes: the spectrum from the metabolic syndrome to type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.512

7 January 2021

Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.512

7 January 2021

Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.512

7 January 2021

Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.512

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.512

7 January 2021

Glucagon response to hypoglycemia is improved by insulin-independent restoration of normoglycemia in diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.512

7 January 2021

Quantitative measurement of islet glucagon response to hypoglycemia by confocal fluorescence imaging in diabetic rats: effects of phlorizin treatment

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.512

7 January 2021

Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.512

7 January 2021

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.512

7 January 2021

Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.512

7 January 2021

Maximum Tubular Reabsorption Capacity for Glucose and Renal Hemodynamics during Rapid Hypertonic Glucose Infusion in Normal and Diabetic Subjects

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.512

7 January 2021

Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.512

7 January 2021

Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.512

7 January 2021

Expression and activity of SGLT2 in diabetes induced by streptozotocin: relationship with the lipid environment

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.512

7 January 2021

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.512

7 January 2021

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.512

7 January 2021

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.512

7 January 2021

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.512

7 January 2021

Beneficial effect of T-1095, a selective inhibitor of renal Na+-glucose cotransporters, on metabolic index and insulin secretion in spontaneously diabetic GK rats.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.512

7 January 2021

Identifiers

DOI

10.1038/KI.2010.512

1 reference

PubMed ID

21358698

Dimensions Publication ID

24 August 2017

0 references

1 reference

PubMed ID

21358698